2 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMORecruiting
In this study, we look at how safe the new medicinal product rusfertide is for the treatment of Polycythemia vera. And how well it works.